ERBB2 and neoplasm: Similarly, when combined with olaparib in BRCA2-deficient xenografts, low-dose HER2-TTC resulted in similar tumor growth inhibition to high-dose HER2-TTC alone, with the combination concluded as being synergistic; by contrast, no synergistic effects were seen with the combination in the parental xenograft model (9).